RBC Capital Markets set a $7.00 price objective on Curis Inc. (NASDAQ:CRIS) in a report released on Wednesday morning. The firm currently has a a buy rating on the stock.

Several other equities analysts also recently issued reports on the stock. Zacks Investment Research raised shares of Curis from a sell rating to a hold rating in a report on Monday, June 27th. Robert W. Baird reissued an outperform rating and set a $7.00 price target on shares of Curis in a report on Wednesday, September 7th. Finally, FBR & Co reissued a buy rating on shares of Curis in a report on Thursday, September 8th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $5.05.

Analyst Recommendations for Curis (NASDAQ:CRIS)

Curis (NASDAQ:CRIS) traded down 1.32% during mid-day trading on Wednesday, hitting $2.99. The stock had a trading volume of 403,235 shares. Curis has a one year low of $1.25 and a one year high of $3.42. The stock’s market cap is $387.12 million. The firm’s 50-day moving average is $2.26 and its 200 day moving average is $1.87.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $2.05 million. Curis had a negative net margin of 526.72% and a negative return on equity of 65.51%. The business’s quarterly revenue was down 19.0% on a year-over-year basis. During the same period last year, the business posted ($0.06) EPS. Equities research analysts expect that Curis will post ($0.37) EPS for the current year.

In other Curis news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The stock was acquired at an average cost of $2.40 per share, with a total value of $24,499,999.20. Following the completion of the purchase, the insider now directly owns 27,328,464 shares in the company, valued at approximately $65,588,313.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.09% of the company’s stock.

Large investors have recently bought and sold shares of the company. Royal Bank of Canada increased its stake in Curis by 0.9% in the second quarter. Royal Bank of Canada now owns 811,129 shares of the company’s stock worth $1,265,000 after buying an additional 7,220 shares during the period. Metropolitan Life Insurance Co. NY acquired a new stake in Curis during the second quarter worth $146,000. Adage Capital Partners GP L.L.C. acquired a new stake in Curis during the second quarter worth $312,000. Barclays PLC increased its stake in Curis by 10,149.4% in the second quarter. Barclays PLC now owns 64,059 shares of the company’s stock worth $100,000 after buying an additional 63,434 shares during the period. Finally, State Street Corp increased its stake in Curis by 8.7% in the second quarter. State Street Corp now owns 1,579,103 shares of the company’s stock worth $2,464,000 after buying an additional 126,694 shares during the period. 52.36% of the stock is owned by institutional investors and hedge funds.

Curis Company Profile

Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.

5 Day Chart for NASDAQ:CRIS

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.